Famitinib
Famitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, and mast/stem cell growth factor receptor Kit.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 3 | 4 | — | — | 8 |
| Lung neoplasms | D008175 | — | C34.90 | — | 4 | 1 | — | — | 5 |
| Uterine cervical neoplasms | D002583 | — | — | — | 2 | 1 | — | — | 3 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 1 | 1 | — | — | 2 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | 1 | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 6 | 4 | — | — | — | 9 |
| Carcinoma | D002277 | — | C80.0 | 2 | 4 | — | — | — | 5 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 3 | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 3 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 2 | 2 | — | — | — | 3 |
| Recurrence | D012008 | — | — | — | 2 | — | — | — | 2 |
| Osteosarcoma | D012516 | — | — | 1 | 1 | — | — | 1 | 2 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | 2 | — | — | — | 2 |
| Disease progression | D018450 | — | — | 1 | 1 | — | — | — | 1 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Famitinib |
| INN | famitinib |
| Description | Famitinib is a tyrosine kinase receptor inhibitor developed by Jiangsu Hengrui for a variety of cancers.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O |
Identifiers
| PDB | — |
| CAS-ID | 1044040-56-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1278146 |
| ChEBI ID | — |
| PubChem CID | 16662431 |
| DrugBank | DB11741 |
| UNII ID | 768FW21J3L (ChemIDplus, GSRS) |
Target
Agency Approved
PDGFRB
PDGFRB
KDR
KDR
KIT
KIT
Organism
Homo sapiens
Gene name
PDGFRB
Gene synonyms
PDGFR, PDGFR1
NCBI Gene ID
Protein name
platelet-derived growth factor receptor beta
Protein synonyms
Activated tyrosine kinase PDGFRB, Beta platelet-derived growth factor receptor, Beta-type platelet-derived growth factor receptor, CD140 antigen-like family member B, CD140b, NDEL1-PDGFRB, PDGF-R-beta, PDGFR-1, PDGFR-beta, Platelet-derived growth factor receptor 1, platelet-derived growth factor receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Pdgfrb (18596)
platelet-derived growth factor receptor beta (P05622)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 350 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use